Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

ByThe Short Paper

This study tested a new treatment called mezigdomide, combined with dexamethasone, for people with multiple myeloma (a type of cancer). The treatment showed promise in patients who had already tried other treatments, including those resistant to lenalidomide and pomalidomide.

In the first phase of the study, they tested the treatment on 77 patients to determine the right dose and schedule and to check for side effects. The most common side effects were problems with the blood (neutropenia) and infections. Based on these results, they decided on the best dose and schedule for the next phase.

In the second phase, 101 patients received the treatment identified in the first phase. These patients had very advanced myeloma and had often tried other treatments, including anti-BCMA therapy. The most common side effects were blood problems and infections, but they were mostly reversible. The treatment led to an overall response in 41% of patients, with a median duration of response of 7.6 months.

In conclusion, the combination of mezigdomide and dexamethasone showed promise in patients with advanced multiple myeloma, with mainly manageable side effects.

Similar Posts

A Key to Protecting Brain Cells in Alzheimer’s, MEG3

ByThe Short Paper

MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease In Alzheimer’s disease, the loss of brain cells is a major problem, but we don’t fully understand why it happens. Scientists did an experiment where they put human and mouse brain cells into mice with Alzheimer’s. They found that only the human brain cells showed…

Simple Summary – C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations

ByThe Short Paper

Link to the article: https://www.nejm.org/doi/full/10.1056/NEJMoa1803185 This study revolves around the usage of a point of care test to guide antibiotic usage in patients with chronic obstructive pulmonary disease (COPD). They tested C-reactive protein (CRP) in patients with COPD. CRP is a inflammatory marker and increased levels are associated with worsening COPD. The study had two groups…

Child wasting and concurrent stunting in low- and middle-income countries

ByThe Short Paper

The goal is to end child malnutrition by 2030, which includes tackling “child wasting,” where kids are too thin for their height. Traditional methods for measuring this problem only give a snapshot, missing when it starts and ends. This study looked at data from 21 groups of children and found that child wasting is a…

Simple Summary – COVID-19 Fatalities, Latitude, Sunlight, and Vitamin D

ByThe Short Paper

Link to the article: https://pubmed.ncbi.nlm.nih.gov/32599103/ Vitamin D has been found to be important for the immune system and typically equator countries tend to have a higher dose due to their location. Looking at 88 countries and available data, they found there was a relationship between latitude and COVID-19 deaths consistent with previous literature. Populations at risk…

Unlocking the Power of Chemical Timekeepers: Oscillatory Systems and Catalytic Wonders

ByThe Short Paper

A catalytically active oscillator made from small organic molecules Oscillatory systems are like regulators in our body, controlling many important processes like metabolism, cell division, and even things like our daily rhythm and heartbeat. Scientists were inspired by chemical oscillations found in non-living things and created synthetic oscillators that work like timekeepers. These synthetic oscillators…

CAR-T Cell Therapy will it work? Biotech Stocks Part 1

ByThe Short Paper

Disclaimer: I do not have a background in finance. I do have a background in medicine. I’m writing about CAR-T cell therapy because it’s been something I’ve been interested in for a while. I am not sure what impact it will have on biotech stocks or company valuations, but I believe it could be significant….